Palliative and Supportive care

EGFRI-Related Skin Toxicity

Information, treatment algorithms and educational materials for healthcare professionals and patients about skin problems that may occur when being treated with anti-EGFR drugs

Multikinase Inhibitor Related Skin Toxicity

Information, treatment algorithms and educational materials for healthcare professionals and patients relating to the management of dermatological toxicities in patients treated with multikinase inhibitors.

Drug-Drug Interactions with Kinase Inhibitors

Information and education online resource for healthcare professionals on drug-drug interactions which can arise from the use of kinase inhibitors

ELCC 2017 Management of Small-cell Lung Cancer

Corinne Faivre-Finn says that personalisation of limited stage SCLC patients’ treatment is the main challenge in this disease.Today the standard of care for stage I, II and III SCLC patients with good performance status is concurrent chemoradiotherapy, regardless of history or tumour size.

There is a lot to learn as to which groups would benefit the most or may develop severe toxicity from the treatment. Immunotherapy has shown some activity in stage IV patients and ongoing studies are looking at the integration of immunotherapy in the treatment of earlier stage patients. Today the safety and efficacy of immunotherapy combined with chemoradiotherapy in first stages SCLC patients still need to be established.